These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
215 related articles for article (PubMed ID: 10910310)
41. Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease. Hatlebakk JG; Berstad A Clin Pharmacokinet; 1996 Nov; 31(5):386-406. PubMed ID: 9118586 [TBL] [Abstract][Full Text] [Related]
42. The management of acid-related dyspepsia in general practice: a comparison of an omeprazole versus an antacid-alginate/ranitidine management strategy. Compete Research Group [corrected]. Mason I; Millar LJ; Sheikh RR; Evans WM; Todd PL; Turbitt ML; Taylor MD Aliment Pharmacol Ther; 1998 Mar; 12(3):263-71. PubMed ID: 9570261 [TBL] [Abstract][Full Text] [Related]
43. Randomized controlled trial comparing the efficacy of mosapride plus omeprazole combination therapy to omeprazole monotherapy in gastroesophageal reflux disease. Yamaji Y; Isomura Y; Yoshida S; Yamada A; Hirata Y; Koike K J Dig Dis; 2014 Sep; 15(9):469-76. PubMed ID: 24957863 [TBL] [Abstract][Full Text] [Related]
44. Double-blind, placebo-controlled study of ranitidine for gastroesophageal reflux symptoms during pregnancy. Larson JD; Patatanian E; Miner PB; Rayburn WF; Robinson MG Obstet Gynecol; 1997 Jul; 90(1):83-7. PubMed ID: 9207819 [TBL] [Abstract][Full Text] [Related]
45. Characteristics of refractory gastroesophageal reflux disease (GERD) symptoms -is switching proton pump inhibitors based on the patient's CYP2C19 genotype an effective management strategy? Takeuchi T; Oota K; Harada S; Edogawa S; Kojima Y; Sanomura M; Sakaguchi M; Hayashi K; Hongoh Y; Itabashi T; Kitae H; Hoshimoto M; Takeuchi N; Higuchi K Intern Med; 2015; 54(2):97-105. PubMed ID: 25742999 [TBL] [Abstract][Full Text] [Related]
46. Treatment of gastroesophageal reflux disease: to step or not to step. McGuigan JE Am J Gastroenterol; 2001 Jun; 96(6):1679-81. PubMed ID: 11419813 [No Abstract] [Full Text] [Related]
47. Proton pump inhibitors or histamine-2 receptor antagonists for the prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis. Harris RA; Kuppermann M; Richter JE Am J Gastroenterol; 1997 Dec; 92(12):2179-87. PubMed ID: 9399748 [TBL] [Abstract][Full Text] [Related]
48. PPIs vs H2RAs for erosive reflux esophagitis. King VJ J Fam Pract; 1998 Mar; 46(3):199-200. PubMed ID: 9519012 [No Abstract] [Full Text] [Related]
49. Economic analysis of alternative treatments for persistent gastro-oesophageal reflux disease. Hillman AL Scand J Gastroenterol Suppl; 1994; 201():98-102. PubMed ID: 8047833 [TBL] [Abstract][Full Text] [Related]
50. pH, healing rate, and symptom relief in patients with GERD. Huang JQ; Hunt RH Yale J Biol Med; 1999; 72(2-3):181-94. PubMed ID: 10780580 [TBL] [Abstract][Full Text] [Related]
51. Omeprazole is more effective than cimetidine in the prevention of recurrence of GERD-associated heartburn and the occurrence of underlying oesophagitis. Bate CM; Green JR; Axon AT; Tildesley G; Murrays FE; Owen SM; Emmas C; Taylor MD Aliment Pharmacol Ther; 1998 Jan; 12(1):41-7. PubMed ID: 9692699 [TBL] [Abstract][Full Text] [Related]
52. "Proton-pump inhibitor-first" strategy versus "step-up" strategy for the acute treatment of reflux esophagitis: a cost-effectiveness analysis in Japan. Habu Y; Maeda K; Kusuda T; Yoshino T; Shio S; Yamazaki M; Hayakumo T; Hayashi K; Watanabe Y; Kawai K J Gastroenterol; 2005 Nov; 40(11):1029-35. PubMed ID: 16322946 [TBL] [Abstract][Full Text] [Related]
53. Clinical trial: the effects of adding ranitidine at night to twice daily omeprazole therapy on nocturnal acid breakthrough and acid reflux in patients with systemic sclerosis--a randomized controlled, cross-over trial. Janiak P; Thumshirn M; Menne D; Fox M; Halim S; Fried M; Brühlmann P; Distler O; Schwizer W Aliment Pharmacol Ther; 2007 Nov; 26(9):1259-65. PubMed ID: 17944740 [TBL] [Abstract][Full Text] [Related]